Image

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Lenvatinib study for liver cancer returning after transplant.

Recruiting
18 years and older
All
Phase 2
  • Simplified description (AI rewritten)
  • Technical description (Original)

Lenvatinib is being studied for treating recurrent hepatocellular carcinoma (HCC) after a liver transplant. HCC is a type of liver cancer. Lenvatinib may help stop tumor growth by blocking enzymes needed for cell growth. This study is important because there are no established treatments for HCC returning after a liver transplant.

Study Details:

  • Participants take lenvatinib by mouth once daily. Treatment cycles last 28 days.
  • Patients are monitored for 30 days after treatment, then every 90 days for up to 2 years.
  • Eligibility: Patients must be 18 or older, have recurrent HCC after liver transplant, and meet specific health criteria.

Key Considerations:

  • Regular visits required during the study.
  • Potential side effects and risks associated with lenvatinib.
  • No established compensation details.

If you are considering joining the study, discuss with your doctor the potential benefits and risks. This study aims to find a new option for patients with recurrent HCC after liver transplant.

Print
Study details
    Recurrent Hepatocellular Carcinoma
    Stage III Hepatocellular Carcinoma AJCC V8
    Stage IIIA Hepatocellular Carcinoma AJCC V8
    Stage IIIB Hepatocellular Carcinoma AJCC V8
    Stage IV Hepatocellular Carcinoma AJCC V8
    Stage IVA Hepatocellular Carcinoma AJCC V8
    Stage IVB Hepatocellular Carcinoma AJCC V8
    Unresectable Hepatocellular Carcinoma

NCT05103904

Emory University

5 January 2025

Contact a study center
Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.